TTI — Thiogenesis Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$30.06m
- CA$26.56m
Annual cashflow statement for Thiogenesis Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | 0.1 | -5.06 | -3.15 |
| Non-Cash Items | — | 0.516 | 0.349 |
| Other Non-Cash Items | |||
| Changes in Working Capital | — | 1.3 | -1.12 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Cash from Operating Activities | 0.1 | -3.25 | -3.92 |
| Other Investing Cash Flow Items | — | 0 | — |
| Sale of Business | |||
| Cash from Investing Activities | — | 0 | — |
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | — | 4.12 | 0.723 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0.1 | 0.88 | -3.23 |